142 related articles for article (PubMed ID: 38845788)
1. Immunization against dengue virus infection is coercive: A timely call.
Ahmed I; Ahamed R; Nahar S; Bari LF; Dewan SMR
Health Sci Rep; 2024 Jun; 7(6):e2170. PubMed ID: 38845788
[TBL] [Abstract][Full Text] [Related]
2. [Dengue fever: from disease to vaccination].
Teyssou R
Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
[TBL] [Abstract][Full Text] [Related]
3. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial.
Walsh MR; Alam MS; Pierce KK; Carmolli M; Alam M; Dickson DM; Bak DM; Afreen S; Nazib F; Golam K; Qadri F; Diehl SA; Durbin AP; Whitehead SS; Haque R; Kirkpatrick BD
Lancet Infect Dis; 2024 Feb; 24(2):150-160. PubMed ID: 37776876
[TBL] [Abstract][Full Text] [Related]
4. A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine.
Valdés I; Izquierdo A; Cobas K; Thao P; Anh Duc H; Duc Loc H; Dung LT; Lazo L; Suzarte E; Pérez Y; Romero Y; Yaugel M; Marcos E; Guzmán MG; Dat DT; Hien ND; Guillén G; Gil L; Hermida L
J Gen Virol; 2019 Jun; 100(6):975-984. PubMed ID: 31090533
[TBL] [Abstract][Full Text] [Related]
5. A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.
Russell KL; Rupp RE; Morales-Ramirez JO; Diaz-Perez C; Andrews CP; Lee AW; Finn TS; Cox KS; Falk Russell A; Schaller MM; Martin JC; Hyatt DM; Gozlan-Kelner S; Bili A; Coller BG
Hum Vaccin Immunother; 2022 Nov; 18(5):2046960. PubMed ID: 35290152
[TBL] [Abstract][Full Text] [Related]
6. Human CD4
Angelo MA; Grifoni A; O'Rourke PH; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
J Virol; 2017 Mar; 91(5):. PubMed ID: 27974563
[TBL] [Abstract][Full Text] [Related]
7. Controlled human infection study underpins efficacy of the tetravalent live-attenuated dengue vaccine TV005.
Wilder-Smith A
J Clin Invest; 2024 Feb; 134(3):. PubMed ID: 38299597
[TBL] [Abstract][Full Text] [Related]
8. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021.
Paz-Bailey G; Adams L; Wong JM; Poehling KA; Chen WH; McNally V; Atmar RL; Waterman SH
MMWR Recomm Rep; 2021 Dec; 70(6):1-16. PubMed ID: 34978547
[TBL] [Abstract][Full Text] [Related]
9. A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.
Thoresen D; Matsuda K; Urakami A; Ngwe Tun MM; Nomura T; Moi ML; Watanabe Y; Ishikawa M; Hau TTT; Yamamoto H; Suzaki Y; Ami Y; Smith JF; Matano T; Morita K; Akahata W
J Virol; 2024 May; 98(5):e0023924. PubMed ID: 38647327
[TBL] [Abstract][Full Text] [Related]
10. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
[TBL] [Abstract][Full Text] [Related]
11. Tracing down the Updates on Dengue Virus-Molecular Biology, Antivirals, and Vaccine Strategies.
Malik S; Ahsan O; Mumtaz H; Tahir Khan M; Sah R; Waheed Y
Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631896
[TBL] [Abstract][Full Text] [Related]
12. Dengue vaccines: Are they safe for travelers?
Halstead SB; Aguiar M
Travel Med Infect Dis; 2016; 14(4):378-83. PubMed ID: 27343438
[TBL] [Abstract][Full Text] [Related]
13. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
Flasche S; Jit M; Rodríguez-Barraquer I; Coudeville L; Recker M; Koelle K; Milne G; Hladish TJ; Perkins TA; Cummings DA; Dorigatti I; Laydon DJ; España G; Kelso J; Longini I; Lourenco J; Pearson CA; Reiner RC; Mier-Y-Terán-Romero L; Vannice K; Ferguson N
PLoS Med; 2016 Nov; 13(11):e1002181. PubMed ID: 27898668
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.
Osorio JE; Velez ID; Thomson C; Lopez L; Jimenez A; Haller AA; Silengo S; Scott J; Boroughs KL; Stovall JL; Luy BE; Arguello J; Beatty ME; Santangelo J; Gordon GS; Huang CY; Stinchcomb DT
Lancet Infect Dis; 2014 Sep; 14(9):830-8. PubMed ID: 25087476
[TBL] [Abstract][Full Text] [Related]
15. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
16. Dengue Fever: Therapeutic Potential of
Sarker MMR; Khan F; Mohamed IN
Front Pharmacol; 2021; 12():610912. PubMed ID: 33981215
[TBL] [Abstract][Full Text] [Related]
17. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
Galula JU; Salem GM; Chang GJ; Chao DY
Hum Vaccin Immunother; 2019; 15(10):2328-2336. PubMed ID: 31314657
[TBL] [Abstract][Full Text] [Related]
18. Latest developments and future directions in dengue vaccines.
Thisyakorn U; Thisyakorn C
Ther Adv Vaccines; 2014 Jan; 2(1):3-9. PubMed ID: 24757522
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States.
Glass A; Polhemus M; Wang D; Jarman RG; Thomas SJ; Friberg H; Currier JR; Bonaparte M; De La Barra R; Princiotta MF; Abbott M; Cuzzo B; Machabert T; Sridhar S; Endy TP
J Infect Dis; 2020 Mar; 221(7):1057-1069. PubMed ID: 31755526
[TBL] [Abstract][Full Text] [Related]
20. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
